AptaBio Therapeutics Inc. (KOSDAQ: A293780)
Health Care · Biotechnology · KR
₩6,800.00
+10.03% today · -15.7% 1Y
AptaBio Therapeutics Inc. (KOSDAQ: A293780) operates in the Biotechnology industry within the Health Care sector. The company is valued at $137.84M.
Over the last twelve months the share price has lost 15.7%, trading between 3.87K and 10.89K.
Tweenvest scores AptaBio Therapeutics Inc. across four factors: quality 31/100, value 62/100. Its strongest factor is value.
A293780 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $137.84M
- Revenue (TTM)
- $2.81M
- P/E
- —
- EPS
- -733.72
- Dividend yield
- —
- Beta (5Y)
- 0.92
- 52-week high
- ₩10,890.00
- 52-week low
- ₩3,870.00
- Avg volume (3M)
- —
- Shares outstanding
- 28.09M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.99 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.